Wound surveillance has been reported to result in a significant fall in the incidence of wound sepsis in total knee arthroplasty (TKA). However, there is currently little guidance on the definition of surgical wound infection that is best to be used for surveillance. The purpose of this study was to assess the agreement between three common definitions of surgical wound infection as a performance indicator in TKA; (a) the CDC 1992 definition, (b) the NINSS modification of the CDC definition and (c) the ASEPSIS scoring method applied to the same series of surgical wounds. A prospective study of 500 surgical wounds in patients who underwent knee arthroplasties between May 2002 and December 2004 from a single tertiary centre were assessed according to the different definitions of surgical wound infection.Introduction
Methods
Up to 2% of total hip arthroplasties (THA) are still complicated by infection. This leads to dissatisfied patients with poor function, and has far-reaching social and economic consequences. The challenge in these cases is the eradication of infection, the restoration of full function and the prevention of recurrence. We report the outcome of early aggressive debridement in the acutely infected THA. We studied 28 consecutive patients referred with acutely infected THA (18 primaries, 10 revisions) which occurred within 6 weeks of the index operation or of haematogenous spread between 1999 and 2006. Microbiology confirmed bacterial colonisation in all cases with 20 early post-operative infections and 8 cases of acute haematogenous spread. Patients with a cemented THA underwent aggressive open debridement, a thorough synovectomy and exchange of all mobile parts. Uncemented THA were treated as a single stage revision with removal of all implants, aggressive debridement and re-implantation of new prosthesis. Antibiotics were continued in all cases until inflammatory markers and the plasma albumin concentration returned to within normal limits.Introduction
Methods
Total knee replacements (TKR) are among the commonest operations performed in orthopaedic practice. Literature review showed that 10-30% of patients who underwent TKR needed 1-3 units of blood. Tranexamic acid (TXA) has been popularised as an effective way to reduce blood loss and subsequent blood transfusion. Our aim was to investigate the value of TXA in reducing blood loss and blood transfusion after TKR and other clinical outcomes such as deep venous thrombosis (DVT), pulmonary embolism (PE), ischaemic heart diseases and mortality. A systematic review and meta-analysis of published randomised and quasi-randomised trials which used TXA to reduce blood loss in knee arthroplasty were conducted.Introduction
Patients and Methods
To investigate the value of tranexamic acid (TA) in reducing blood loss and blood transfusion after TKR and other clinical outcomes such as deep venous thrombosis (DVT), pulmonary embolism (PE), ischaemic heart diseases and mortality. A systematic review and meta-analysis of published randomised and quasi-randomised trials which used TA to reduce blood loss in knee arthroplasty was conducted. The data was evaluated using the generic evaluation tool designed by the Cochrane Bone, Joint and Muscle Trauma Group.Objectives
Methods
Up to 2% of total knee arthroplasties (TKA) are still complicated by infection. This leads to dissatisfied patients with poor function, and has far-reaching social and economic consequences. The challenge in these cases is the eradication of infection, the restoration of full function and the prevention of recurrence. We report the outcome of prosthesis sparing early aggressive debridement in the acutely infected TKA. We studied 29 consecutive patients referred with acutely infected TKA (18 primaries, 11 revisions) which occurred within 6 weeks of the index operation or of haematogenous spread. Microbiology confirmed bacterial colonisation in all cases with 20 early post-operative infections and 9 cases of acute haematogenous spread. All patients underwent aggressive open debridement, a thorough synovectomy and a change of insert. Antibiotics were continued until inflammatory markers and the plasma albumin concentration returned to within normal limits.Introduction
Methods
Literature review showed that 20–70% of patients who underwent THR needed 1–3 units of blood. Although safer than ever, allogeneic transfusion is still associated with risks for the recipient. There has been unsettled search for ways to reduce such blood loss and transfusion. Tranexamic acid has been popularised as an effective way to reduce blood loss and subsequent blood transfusion.
Blood loss
Seven studies (250 patients) were eligible for this outcome. Using Tranexamic acid reduced blood loss by an average of 155 ml (P-value <
0.00001, 95% CI (87–224), Heterogeneity I2 69 %.) Blood transfusion
Nine studies (463 patients) were eligible for this outcome. Tranexamic acid led to a reduction in the proportion of patients requiring blood transfusion (Odds Ratio of 0.35, P- value <
0.00001, 95% CI (0.22–0.55), Heterogeneity I2 25 %.) Other outcomes
There were no significant differences in the length of stay, DVT, PE, mortality, wound haematoma or infections between the study groups.
Since the era of total knee replacement (TKR) began in the late 1960s, total knee replacement has become one of the commonest operations in orthopaedic practice. TKR is frequently associated with transfusion of allogenic blood Benoni G 1995; Seppo T 1997. In our centre, 30 % of patients who had undergone TKR received allogenc blood transfusion perioperatively. Although, serological screening has reduced the risk for viral infection to a very low levelKlein HG 1995; Schreiber GB 1996, the public is still concerned about this potential serious complication. Allogenic blood transfusion can be also associated with other non infectious complications such as haemolysis, immunosuppression, transfusion-related acute lung injury and even death.Madjdpour C 2005 Therefore, further refinement of strategies to avoid exposure to allogeneic blood is needed. Amongst the technologies to minimise the need for blood transfusion is the use of the anti-fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon amino-caproic acid (EACA).New Reference